MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Source :: GlobeNewswire. March 9, 2023
Publication Year :: 2023
Abstract: LA JOLLA, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock [...]

Subjects :: United States. Biomedical Advanced Research and Development Authority
United States. Department of Health and Human Services
Tokyo Stock Exchange, Inc. -- Contracts
Social service
Stock-exchange
Securities industry -- Contracts
Acute respiratory distress syndrome
Industrial research -- Japan
Research and development
Securities industry
Contract agreement
Banking, finance and accounting industries
Business

Tools